نتائج البحث - Peter Vandenberghe

تنقيح النتائج
  1. 1
    Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia

    Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia حسب Els Lierman, Dominik Selleslag, Sanne Smits, Johan Billiet, Peter Vandenberghe

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) حسب Bartosz Wasąg, Els Lierman, Mira Meeus, Jan Cools, Peter Vandenberghe

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model

    CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model حسب Stefaan W. Van Gool, Peter Vandenberghe, Mark de Boer, Jan Ceuppens

    منشور في 1996
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases حسب Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

    منشور في 2012
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines

    The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines حسب Jan Delabie, Jan Ceuppens, Peter Vandenberghe, Mark de Boer, Lieve Coorevits, Chris Peeters

    منشور في 1993
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation

    Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation حسب Katherine Vandenborre, Stefaan W. Van Gool, Ahmad Kasran, Jan Ceuppens, M. Boogaerts, Peter Vandenberghe

    منشور في 1999
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances

    Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances حسب Sabine Franke, Iwona Włodarska, Brigitte Maes, Peter Vandenberghe, Jan Delabie, Anne Hagemeijer, Chris De Wolf‐Peeters

    منشور في 2001
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern حسب José Luis Ferreiro, Julie Morscio, Daan Dierickx, Lukas Marcelis, G. Verhoef, Peter Vandenberghe, Thomas Tousseyn, Iwona Wlodarska

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

    Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data حسب Gils Roex, Tom Feys, Yves Béguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

    Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for I... حسب Johan Maertens, Jan Verhaegen, Hilde Demuynck, Penelope Brock, Gregor Verhoef, Peter Vandenberghe, Johan Van Eldere, L. Verbist, Marc Boogaerts

    منشور في 1999
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features

    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features حسب José Luis Ferreiro, Julie Morscio, Daan Dierickx, Peter Vandenberghe, Olivier Gheysens, G. Verhoef, M. Zamani, Thomas Tousseyn, Iwona Włodarska

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

    Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others... حسب Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, José Thomas, Peter Vandenberghe, Jan Balzarini, Christine De Wolf‐Peeters, Luc Mortelmans, Gregor Verhoef

    منشور في 2001
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation حسب Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dębiec‐Rychter

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes

    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes حسب Michel Delforge, H Demuynck, Peter Vandenberghe, G. Verhoef, Pierre Zachée, V. Van Duppen, P Marijnen, Herman Van den Berghe, MA Boogaerts

    منشور في 1995
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant حسب Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis

    B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis حسب Zhanju Liu, Karel Geboes, Peter W. Hellings, Philippe Maerten, Hubertine Heremans, Peter Vandenberghe, Louis Boon, Peter van Kooten, Paul Rutgeerts, Jan Ceuppens

    منشور في 2001
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma حسب Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, José Thomas, Tjibbe de Groot, Jan Balzarini, C. De Wolf‐Peeters, L. Mortelmans, G. Verhoef

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas

    Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas حسب Iwona Włodarska, Daan Dierickx, Vera Vanhentenrijk, Katrien Van Roosbroeck, H Pospíšilová, Francesca Minnei, Gregor Verhoef, José Thomas, Peter Vandenberghe, Chris De Wolf‐Peeters

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia حسب Kim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, Cedric Folens, Leander Van Neste, Sofie Bekaert, Peter Vandenberghe, María D. Odero, Peter Marynen, Jan Cools

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions حسب Katrien Van Roosbroeck, Jan Cools, Daan Dierickx, José Thomas, Peter Vandenberghe, Michel Stul, Jan Delabie, Chris De Wolf‐Peeters, Peter Marynen, Iwona Włodarska

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: